Sapna Tibrewal1, Yair Ivanir1, Joy Sarkar1, Neema Nayeb-Hashemi2, Charles S Bouchard2, Eunjae Kim1, Sandeep Jain1. 1. Corneal Neurobiology Laboratory, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, College of Medicine, Chicago, Illinois, United States. 2. Department of Ophthalmology, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois, United States.
Abstract
PURPOSE: To determine if hyperosmolar stress can stimulate human neutrophils to form neutrophil extracellular traps (NETs) and to investigate potential strategies to reduce formation of NETs (NETosis) in a hyperosmolar environment. METHODS: Neutrophils were isolated from peripheral venous blood of healthy subjects and incubated in iso-osmolar (280 mOsM) or hyperosmolar (420 mOsM) media for 4 hours. Neutrophil extracellular traps were quantified using a PicoGreen dye assay to measure extracellular DNA. Two known inhibitors of NETosis, staurosporine and anti-β2 integrin blocking antibody, and two proresolution formyl peptide receptor 2 (FPR2) agonists, annexin/lipocortin-1 mimetic peptide and 15-epi-lipoxin A4, were evaluated as possible strategies to reduce hyperosmolarity-induced NETosis. RESULTS: The amount of NETs induced by hyperosmolar medium (420 mOsM) increased linearly over time to 3.2 ± 0.3 times that induced by iso-osmolar medium at 4 hours (P < 0.05). NETosis increased exponentially with increasing osmolarity and was independent of the stimulus used to increase osmolarity. Upon neutrophil exposure to hyperosmolar stress, restoration of iso-osmolar conditions decreased NET formation by 52.7% ± 5% (P < 0.05) but did not completely abrogate it. Among the strategies tested to reduce NETosis in a hyperosmolar environment, annexin-1 peptide was the most efficacious. CONCLUSIONS: Hyperosmolarity induces formation of NETs by neutrophils. This NETosis mechanism may explain the presence of excessive NETs on the ocular surface of patients with dry eye disease. Because they reduce hyperosmolarity-induced NETosis, FPR2 agonists may have therapeutic potential in these patients. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
PURPOSE: To determine if hyperosmolar stress can stimulate human neutrophils to form neutrophil extracellular traps (NETs) and to investigate potential strategies to reduce formation of NETs (NETosis) in a hyperosmolar environment. METHODS: Neutrophils were isolated from peripheral venous blood of healthy subjects and incubated in iso-osmolar (280 mOsM) or hyperosmolar (420 mOsM) media for 4 hours. Neutrophil extracellular traps were quantified using a PicoGreen dye assay to measure extracellular DNA. Two known inhibitors of NETosis, staurosporine and anti-β2 integrin blocking antibody, and two proresolution formyl peptide receptor 2 (FPR2) agonists, annexin/lipocortin-1 mimetic peptide and 15-epi-lipoxin A4, were evaluated as possible strategies to reduce hyperosmolarity-induced NETosis. RESULTS: The amount of NETs induced by hyperosmolar medium (420 mOsM) increased linearly over time to 3.2 ± 0.3 times that induced by iso-osmolar medium at 4 hours (P < 0.05). NETosis increased exponentially with increasing osmolarity and was independent of the stimulus used to increase osmolarity. Upon neutrophil exposure to hyperosmolar stress, restoration of iso-osmolar conditions decreased NET formation by 52.7% ± 5% (P < 0.05) but did not completely abrogate it. Among the strategies tested to reduce NETosis in a hyperosmolar environment, annexin-1 peptide was the most efficacious. CONCLUSIONS: Hyperosmolarity induces formation of NETs by neutrophils. This NETosis mechanism may explain the presence of excessive NETs on the ocular surface of patients with dry eye disease. Because they reduce hyperosmolarity-induced NETosis, FPR2 agonists may have therapeutic potential in these patients. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
Authors: L Zheng; E H Walters; C Ward; N Wang; B Orsida; H Whitford; T J Williams; T Kotsimbos; G I Snell Journal: Thorax Date: 2000-01 Impact factor: 9.139
Authors: Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy Journal: Pharmacol Rev Date: 2009-06-04 Impact factor: 25.468
Authors: C N Serhan; J F Maddox; N A Petasis; I Akritopoulou-Zanze; A Papayianni; H R Brady; S P Colgan; J L Madara Journal: Biochemistry Date: 1995-11-07 Impact factor: 3.162
Authors: Anirban Banerjee; Ernest E Moore; Nathan J McLaughlin; Luis Lee; Wilbert L Jones; Jeffrey L Johnson; Trevor L Nydam; Christopher C Silliman Journal: Shock Date: 2013-04 Impact factor: 3.454
Authors: Geraint P Williams; Peter Nightingale; Sue Southworth; Alastair K O Denniston; Paul J Tomlins; Stephen Turner; John Hamburger; Simon J Bowman; S John Curnow; Saaeha Rauz Journal: Invest Ophthalmol Vis Sci Date: 2016-10-01 Impact factor: 4.799